August 28, 2023

APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development, will lead the strategy and execution of the company’s clinical therapeutic and diagnostic programs CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company

Vahanna Tech Edge Acquisition I Corporation Announces Shareholder Approval of Business Combination with Roadzen, Inc. on August 25, 2023

NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) — Vahanna Tech Edge Acquisition I Corp. (Nasdaq: VHNAU, VHNA, VHNAW) (“Vahanna”), a publicly traded special purpose acquisition company, and Roadzen, Inc. (“Roadzen” or the “Company”), a global insurance technology company on a mission to transform global auto insurance powered by advanced AI,